The role of prostaglandin analogues and minimally invasive glaucoma surgery in long-term disease control: a case based-review Case report

Main Article Content

Jakub Gajdecki
Anna Michalska
Paweł Stala

Abstract

Purpose: To present a case of long-term primary open angle glaucoma management and discuss various therapeutical approaches.


Case: During a 11-year long follow-up period of a 58-year-old woman with primary open angle glaucoma we observed signs of disease progression despite intraocular pressure within normal range and triple anti-glaucomatous therapy. Proper switch of therapeutic agent together with implementation of minimally invasive glaucoma surgery helped to maintain a stable condition.


Conclusion: Regular monitoring of glaucoma patients is crucial for recognition of early signs of progression in order to properly amend the pharmacotherapy or implement adequate surgical treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Gajdecki J, Michalska A, Stala P. The role of prostaglandin analogues and minimally invasive glaucoma surgery in long-term disease control: a case based-review. Ophthatherapy [Internet]. 2026Nov.20 [cited 2026Nov.22];00:A132126. Available from: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/3487
Section
Surgery and laser therapy

References

1. Leske M, Heijl A, Hussein M et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1): 48-56.
2. Mills R, Budenz D, Lee P et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006; 141(1): 24-30.
3. Coleman A, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008; 53(Suppl. 1): S3-10.
4. Jiang X, Varma R, Wu S et al.; Los Angeles Latino Eye Study Group. Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles Latino Eye Study. Ophthalmology. 2012; 119(11): 2245-53.
5. Baskaran M, Foo R, Cheng C et al. The Prevalence and Types of Glaucoma in an Urban Chinese Population: The Singapore Chinese Eye Study. JAMA Ophthalmol. 2015; 133(8): 874-80.
6. Jammal A, Berchuck S, Thompson A et al. The Effect of Age on Increasing Susceptibility to Retinal Nerve Fiber Layer Loss in Glaucoma. Invest Ophthalmol Vis Sci. 2020; 61(13): 8.
7. Hollows F, Graham P. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol. 1966; 50(10): 570-86.
8. Bankes J, Perkins E, Tsolakis S et al. Bedford glaucoma survey. Br Med J. 1968; 1(5595): 791-6.
9. Bengtsson B. The prevalence of glaucoma. Br J Ophthalmol. 1981; 65(1): 46-9.
10. Mitchell P, Smith W, Attebo K et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996; 103(10): 1661-9.
11. Giuffrè G, Giammanco R, Dardanoni G et al. Prevalence of glaucoma and distribution of intraocular pressure in a population. The Casteldaccia Eye Study. Acta Ophthalmol Scand. 1995; 73(3): 222-5.
12. Kahn H, Leibowitz H, Ganley J et al.; The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol. 1977; 106(1): 17-32.
13. Tielsch J, Sommer A, Katz J et al. Racial variation in the prevalence of primary open angle glaucoma. JAMA. 1991; 266(3): 369-74.
14. Cedrone C, Culasso F, Cesareo M et al. Prevalence of glaucoma in Ponza, Italy: a comparison with other studies. Ophthalmic Epidemiol. 1997; 4(2): 59-72.
15. Fung A, Reid S, Jones M et al. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol. 2007; 91(1): 62-8.
16. Kampik A, Arias-Puente A, O’Brart D et al.; European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer masked multicenter study. J Glaucoma. 2002; 11(2): 90-6.
17. Camras C, Sheu W; United States Latanoprost-Brimonidine Study Group. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma. 2005; 14(2): 161-7.
18. Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014; 8: 1967-85.
19. Francis BA, Winarko J. Ab interno Schlemm’s canal surgery: trabectome and i-stent. Dev Ophthalmol. 2012; 50: 125-36.
20. Le K, Saheb H. iStent trabecular micro-bypass stent for open-angle glaucoma. Clin Ophthalmol. 2014; 8: 1937-45.
21. Guedes RAP, Gravina DM, Lake JC et al. Intermediate Results of iStent or iStent inject Implantation Combined with Cataract Surgery in a Real-World Setting: A Longitudinal Retrospective Study. Ophthalmol Ther. 2019; 8(1): 87-100.
22. Jea SY, Francis BA, Vakili G et al. Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. Ophthalmology. 2012; 119(1): 36-42.
23. Pantcheva MB, Kahook MY. Ab interno trabeculectomy. Middle East Afr J Ophthalmol. 2010; 17(4): 287-9.
24. Al Yousef Y, Strzalkowska A, Hillenkamp J et al. Comparison of a second-generation trabecular bypass (iStent inject) to ab interno trabeculectomy (Trabectome) by exact matching. Graefes Arch Clin Exp Ophthalmol. 2020; 258(12): 2775-80.